Biovica signs laboratory services agreement with leading U.S. cancer center
Biovica signs laboratory services agreement with leading U.S. cancer center
Biovica, a company specializing in blood-based cancer monitoring, today announced that it has entered into a laboratory services agreement with one of the leading cancer centers in the United States, designated by the National Cancer Institute as a Comprehensive Cancer Center.
The agreement establishes the framework for the cancer center to access DiviTum® TKa testing services through Biovica’s CLIA-certified laboratory in San Diego. DiviTum TKa is an FDA 510(k)-cleared blood-based biomarker test used as an aid in monitoring disease progression in hormone receptor-positive metastatic breast cancer.
The agreement represents another step in expanding the availability of DiviTum TKa at leading cancer institutions in the United States and supports Biovica’s strategy to increase the clinical adoption of the test.
“Signing an agreement with a leading NCI-designated Comprehensive Cancer Center is an important achievement for Biovica. It further strengthens our presence among leading U.S. cancer institutions and creates a foundation for increased use of DiviTum TKa in clinical practice,” said Theis Kipling, CEO of Biovica.